

SPECIALTY GUIDELINE MANAGEMENT

AUBAGIO (teriflunomide) Teriflunomide

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indication

Aubagio is indicated for the treatment of patients with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

All other indications are considered experimental/investigational and not medically necessary.

II. PRESCRIBER SPECIALTIES

This medication must be prescribed by or in consultation with a neurologist.

III. CRITERIA FOR INITIAL APPROVAL

A. Relapsing forms of multiple sclerosis

Authorization of 12 months may be granted to members who have been diagnosed with a relapsing form of multiple sclerosis (including relapsing-remitting and secondary progressive disease for those who continue to experience relapse).

B. Clinically isolated syndrome

Authorization of 12 months may be granted to members for the treatment of clinically isolated syndrome of multiple sclerosis.

IV. CONTINUATION OF THERAPY

For all indications: Authorization of 12 months may be granted to members who are experiencing disease stability or improvement while receiving Aubagio.

V. OTHER CRITERIA

- A. Members will not use Aubagio concomitantly with other disease modifying multiple sclerosis agents (Note: Ampyra and Nuedexta are not disease modifying).
- B. Authorization may be granted for pediatric members less than 18 years of age when benefits outweigh risks.

VI. REFERENCE

1. Aubagio [package insert]. Cambridge, MA: Genzyme Corporation; December 2022.

PAHUB Questions

1. Is this an initial request? *If YES, go to 3. If NO, go to 2.*
2. Has the patient experienced disease stability or improvement while receiving teriflunomide? *If YES, approve x 12 months. If NO, refer to Medical Director.*

Reference number(s)
1808-A

3. Has the patient been diagnosed with a relapsing form of multiple sclerosis (including relapsing-remitting and secondary progressive disease for those who continue to experience relapse)? *If YES, go to 5. If NO, go to 4.*
4. Has the patient been diagnosed with clinically isolated syndrome of multiple sclerosis? *If YES, go to 5. If NO, refer to Medical Director.*
5. Will the patient be using teriflunomide concomitantly with other disease modifying multiple sclerosis agents (Note: Ampyra and Nuedexta are not disease modifying)? *If YES, refer to Medical Director. If NO, go to 6.*
6. Is the patient 18 years of age or older? *If YES, approve x 12 months. If NO, go to 7.*
7. Do the benefits of taking teriflunomide outweigh the risks? *If YES, approve x 12 months. If NO, refer to Medical Director.*